At Close: 4:00 PM
AbbVie Stock Price Graph
AbbVie Stock Price Today
AbbVie Inc. (ABBV) stock rallied over 1.31% intraday to trade at $151.24 a share on NYSE. The stock opened with a loss of -7.04% at $138.77 and touched an intraday high of $143.00, rising 1.31% against the last close of $149.28. The AbbVie Inc. in stock market went to a low of $136.03 during the session.
AbbVie Stock Snapshot
Number of Shares
Cash Flow per Share
Free Float in %
AbbVie Stock Price History Chart
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Frequently Asked Questions
What is the current AbbVie Inc. (ABBV) stock price?
AbbVie Inc. (NYSE: ABBV) stock price is $151.24 in the last trading session. During the trading session, ABBV stock reached the peak price of $143.00 while $136.03 was the lowest point it dropped to. The percentage change in ABBV stock occurred in the recent session was 1.31% while the dollar amount for the price change in ABBV stock was $1.96.
ABBV's industry and sector of operation?
The NYSE listed ABBV is part of Drug Manufacturers—General industry that operates in the broader Healthcare sector. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.
Who are the executives of ABBV?
Mr. Jeffrey Ryan Stewart
Executive Vice President & Chief Commercial Officer
Dr. Azita Saleki-Gerhardt Ph.D.
Executive Vice President of Operations
Mr. Scott T. Reents
Senior Vice President & Chief Financial Officer
Mr. Richard A. Gonzalez
Chairman & Chief Executive Officer
How ABBV did perform over past 52-week?
ABBV's closing price is 0.10% higher than its 52-week low of $130.96 where as its distance from 52-week high of $168.11 is -0.12%.
How many employees does ABBV have?
Number of ABBV employees currently stands at N/A. ABBV operates from 1 North Waukegan Road, North Chicago, IL 60064-6400, US.
Link for ABBV official website?
Official Website of ABBV is: https://www.abbvie.com
How do I contact ABBV?
How many shares of ABBV are traded daily?
ABBV stock volume for the day was 6088892.00 shares. The average number of ABBV shares traded daily for last 3 months was 4.95 Million.
What is the market cap of ABBV currently?
The market value of ABBV currently stands at $267.02 Billion with its latest stock price at $151.24 and N/A of its shares outstanding.